Skip to main content

Table 1 Summary of milestone assessments

From: Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial

Assessment

Baseline

Month 6 (midpoint)

Month 12 (final)

Withdrawala

Extension studyb

DAS28 (ESR) and Extended Joint Count

X

X

X

X

X

CRP

X

X

X

X

X

Assessor global rating (VAS)

X

X

X

X

X

Pain rating (VAS)

X

X

X

X

X

Fatigue rating (VAS)

X

X

X

X

X

RA medication

X

X

X

X

X

Medical history

X

    

Alcohol consumption

X

    

Smoking history/status

X

X

X

X

 

X-rays (plain, of hands and feet)

X

 

X

X

 

HAQ

X

X

X

X

X

CSRI

X

X

X

X

 

EQ-5D-5 L

X

X

X

X

X

PHQ-9

X

    

GAD-7

X

    

MARS

X

X

X

X

 

BIPQ

X

    

BMQ

X

    

Views of RA treatment

X

 

X

X

 

Adverse events

 

X

X

X

X

  1. DAS28-ESR will be calculated from joint count, patient global rating (VAS) and ESR during every visit; SDAI will be calculated from joint count, patient global rating (VAS), assessor global rating (VAS) and CRP at baseline, midpoint and final assessments
  2. aTo be completed at any time during the trial if the patient withdraws. bExtension study only
  3. BIPQ Brief Illness Perceptions Questionnaire, BMQ Beliefs about Medicines Questionnaire, CRP C-reactive protein, CSRI Modified Client Service Receipt Inventory, EQ-5D-5 L EuroQol 5-dimensional 5-level score, ESR erythrocyte sedimentation rate, GAD-7 Generalized Anxiety disorder-7, HAQ Health Assessment Questionnaire, MARS Medication Adherence Rating Scale, PHQ-9 Patient Health Questionnaire-9, RA rheumatoid arthritis, SDAI Simplified Disease Activity Index, VAS Visual Analogue Scale
Back to article page

Trials

ISSN: 1745-6215